The state of Washington currently has 5 active clinical trials seeking participants for Epilepsy research studies. These trials are conducted in various cities, including Seattle, Spokane, Tacoma and Vancouver.
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
Recruiting
This trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures. Eligible Subjects, adults and adolescents, will continue to take their usual AEDs and receive either cenobamate or placebo. Subjects will have a 50% chance or receiving cenobamate or placebo (sugar pill). Subjects will initially receive 12.5 mg of cenobamate or placebo (study drug) and increase the dose every two weeks until they reach a target dos... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
02/27/2024
Locations: Valley Medical Center, Renton, Washington +1 locations
Conditions: Primary Generalized Epilepsy
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
Recruiting
The purpose of the study is to evaluate the efficacy of lacosamide (LCM) versus an Active Comparator chosen based on standard of care (StOC) in severe and nonsevere seizure burden (defined as total minutes of electroencephalographic neonatal seizures (ENS) per hour) in neonates with seizures that are not adequately controlled with previous anti-epileptic drug (AED) treatment.
Gender:
All
Ages:
28 days and below
Trial Updated:
11/20/2023
Locations: Sp0968 122, Seattle, Washington
Conditions: Electroencephalographic Neonatal Seizures, Epilepsy
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
Recruiting
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants. This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).
Gender:
All
Ages:
Between 1 day and 6 months
Trial Updated:
08/21/2023
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Tuberous Sclerosis Complex, Epilepsy
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
Recruiting
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions over a 2-week period. The subjects will be followed for an additional 10 weeks post treatment. Quality of Life questionnaires and adverse even... Read More
Gender:
All
Ages:
9 years and above
Trial Updated:
07/21/2023
Locations: Seattle Children's Hospital, University of Washington, Seattle, Washington
Conditions: Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic
Microgrid II - Electrocorticography Signals for Human Hand Prosthetics
Recruiting
Neurologic disease with loss of motor function is a major health burden. Brain-computer interfaces (BCI) are systems that use brain signals to power an external device, such as a communication board or a prosthetic device, which may help people with loss of motor function. Electrocorticography (ECoG) has been used to decode hand movements and as a control signal for brain-computer interface (BCI). This study hopes to use a smaller spacing of ECoG to see if a better motor signal can be found and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2021
Locations: Harborview Medical Center, Seattle, Washington
Conditions: Epilepsy Intractable